(FRE) Fresenius SE & Co. KGaA - Ratings and Ratios
Exchange: XETRA •
Country: Germany •
Currency: EUR •
Type: Common Stock •
ISIN: DE0005785604
Dialyzers, Infusion, Nutrition, Devices
FRE EPS (Earnings per Share)
FRE Revenue
Description: FRE Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA (XETRA:FRE) is a German-based, diversified health-care group that serves chronically ill patients through four operating segments: Fresenius Medical Care (dialysis products and services), Fresenius Kabi (critical-care nutrition, infusion therapies, and medical devices), Fresenius Helios (hospital and nursing-care facilities), and Fresenius Vamed (health-care facility management and patient services). The company traces its roots to 1912 and adopted its current legal form in 2011.
Key financial metrics (FY 2023) show total revenue of €41.0 bn, with Fresenius Medical Care contributing roughly 55 % of that total. The segment’s EBITDA margin hovered around 30 % on a reported basis, reflecting high-margin recurring dialysis services, while Fresenius Kabi delivered a 12 % EBITDA margin, driven by growth in parenteral nutrition and infusion-pump sales.
Sector drivers that materially affect FRE’s outlook include: (1) demographic aging and rising prevalence of chronic kidney disease, which underpins long-term demand for dialysis; (2) tightening reimbursement regimes in Europe and the United States, pressuring pricing power; and (3) supply-chain resilience for sterile manufacturing, a critical factor for Fresenius Kabi’s nutrition and infusion products.
For a deeper quantitative dive, the ValueRay platform offers a granular breakdown of FRE’s valuation multiples and scenario analyses.
FRE Stock Overview
| Market Cap in USD | 31,340m |
| Sub-Industry | Health Care Facilities |
| IPO / Inception |
FRE Stock Ratings
| Growth Rating | 77.8% |
| Fundamental | 47.8% |
| Dividend Rating | 24.6% |
| Return 12m vs S&P 500 | 25.0% |
| Analyst Rating | - |
FRE Dividends
| Dividend Yield 12m | 2.12% |
| Yield on Cost 5y | 3.11% |
| Annual Growth 5y | -18.15% |
| Payout Consistency | 83.5% |
| Payout Ratio | 31.5% |
FRE Growth Ratios
| Growth Correlation 3m | 74.3% |
| Growth Correlation 12m | 95.2% |
| Growth Correlation 5y | 7.7% |
| CAGR 5y | 29.06% |
| CAGR/Max DD 3y (Calmar Ratio) | 1.32 |
| CAGR/Mean DD 3y (Pain Ratio) | 4.60 |
| Sharpe Ratio 12m | 1.37 |
| Alpha | 30.32 |
| Beta | 1.016 |
| Volatility | 26.69% |
| Current Volume | 931k |
| Average Volume 20d | 632k |
| Stop Loss | 45.7 (-3.2%) |
| Signal | -0.34 |
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income (1.12b TTM) > 0 and > 6% of Revenue (6% = 1.33b TTM) |
| FCFTA 0.03 (>2.0%) and ΔFCFTA -4.53pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 11.63% (prev 12.06%; Δ -0.43pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.05 (>3.0%) and CFO 2.21b > Net Income 1.12b (YES >=105%, WARN >=100%) |
| Net Debt (11.63b) to EBITDA (3.33b) ratio: 3.49 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.31 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (569.0m) change vs 12m ago 0.67% (target <= -2.0% for YES) |
| Gross Margin 25.40% (prev 23.25%; Δ 2.16pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 52.40% (prev 51.39%; Δ 1.02pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 5.83 (EBITDA TTM 3.33b / Interest Expense TTM 379.0m) >= 6 (WARN >= 3) |
Altman Z'' 2.52
| (A) 0.06 = (Total Current Assets 10.88b - Total Current Liabilities 8.30b) / Total Assets 41.32b |
| (B) 0.34 = Retained Earnings (Balance) 14.04b / Total Assets 41.32b |
| (C) 0.05 = EBIT TTM 2.21b / Avg Total Assets 42.42b |
| (D) 0.62 = Book Value of Equity 13.97b / Total Liabilities 22.38b |
| Total Rating: 2.52 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 47.76
| 1. Piotroski 4.50pt = -0.50 |
| 2. FCF Yield 3.23% = 1.61 |
| 3. FCF Margin 5.57% = 1.39 |
| 4. Debt/Equity 0.70 = 2.26 |
| 5. Debt/Ebitda 3.49 = -2.30 |
| 6. ROIC - WACC (= -1.73)% = -2.16 |
| 7. RoE 5.92% = 0.49 |
| 8. Rev. Trend -82.06% = -6.15 |
| 9. EPS Trend 62.41% = 3.12 |
What is the price of FRE shares?
As of October 17, 2025, the stock is trading at EUR 47.21 with a total of 930,957 shares traded.
Over the past week, the price has changed by -1.95%, over one month by +0.19%, over three months by +15.32% and over the past year by +43.54%.
Over the past week, the price has changed by -1.95%, over one month by +0.19%, over three months by +15.32% and over the past year by +43.54%.
Is Fresenius SE & Co. KGaA a good stock to buy?
No, based on ValueRay´s Fundamental Analyses, Fresenius SE & Co. KGaA (XETRA:FRE) is currently (October 2025)
a stock to sell. It has a ValueRay Fundamental Rating of 47.76 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of FRE is around 48.11 EUR . This means that FRE is currently overvalued and has a potential downside of 1.91%.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of FRE is around 48.11 EUR . This means that FRE is currently overvalued and has a potential downside of 1.91%.
Is FRE a buy, sell or hold?
Fresenius SE & Co. KGaA has no consensus analysts rating.
What are the forecasts/targets for the FRE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 50 | 5.8% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 52.8 | 11.8% |
FRE Fundamental Data Overview
Market Cap USD = 31.34b (26.87b EUR * 1.1665 EUR.USD)
Market Cap EUR = 26.87b (26.87b EUR * 1.0 EUR.EUR)
P/E Trailing = 23.6139
P/E Forward = 13.089
P/S = 1.2061
P/B = 1.4529
P/EG = 0.3848
Beta = 1.016
Revenue TTM = 22.23b EUR
EBIT TTM = 2.21b EUR
EBITDA TTM = 3.33b EUR
Long Term Debt = 9.31b EUR (from longTermDebt, last quarter)
Short Term Debt = 2.26b EUR (from shortTermDebt, last quarter)
Debt = 12.85b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 11.63b EUR (from netDebt column, last quarter)
Enterprise Value = 38.33b EUR (26.87b + Debt 12.85b - CCE 1.39b)
Interest Coverage Ratio = 5.83 (Ebit TTM 2.21b / Interest Expense TTM 379.0m)
FCF Yield = 3.23% (FCF TTM 1.24b / Enterprise Value 38.33b)
FCF Margin = 5.57% (FCF TTM 1.24b / Revenue TTM 22.23b)
Net Margin = 5.06% (Net Income TTM 1.12b / Revenue TTM 22.23b)
Gross Margin = 25.40% ((Revenue TTM 22.23b - Cost of Revenue TTM 16.58b) / Revenue TTM)
Gross Margin QoQ = 26.12% (prev 24.97%)
Tobins Q-Ratio = 0.93 (Enterprise Value 38.33b / Total Assets 41.32b)
Interest Expense / Debt = 0.67% (Interest Expense 86.0m / Debt 12.85b)
Taxrate = 29.74% (146.0m / 491.0m)
NOPAT = 1.55b (EBIT 2.21b * (1 - 29.74%))
Current Ratio = 1.31 (Total Current Assets 10.88b / Total Current Liabilities 8.30b)
Debt / Equity = 0.70 (Debt 12.85b / totalStockholderEquity, last quarter 18.28b)
Debt / EBITDA = 3.49 (Net Debt 11.63b / EBITDA 3.33b)
Debt / FCF = 9.40 (Net Debt 11.63b / FCF TTM 1.24b)
Total Stockholder Equity = 19.01b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.72% (Net Income 1.12b / Total Assets 41.32b)
RoE = 5.92% (Net Income TTM 1.12b / Total Stockholder Equity 19.01b)
RoCE = 7.80% (EBIT 2.21b / Capital Employed (Equity 19.01b + L.T.Debt 9.31b))
RoIC = 5.02% (NOPAT 1.55b / Invested Capital 30.88b)
WACC = 6.75% (E(26.87b)/V(39.72b) * Re(9.76%) + D(12.85b)/V(39.72b) * Rd(0.67%) * (1-Tc(0.30)))
Discount Rate = 9.76% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 81.65 | Cagr: 0.51%
[DCF Debug] Terminal Value 70.17% ; FCFE base≈2.05b ; Y1≈1.83b ; Y5≈1.56b
Fair Price DCF = 37.64 (DCF Value 21.20b / Shares Outstanding 563.2m; 5y FCF grow -13.08% → 3.0% )
EPS Correlation: 62.41 | EPS CAGR: 10.57% | SUE: 0.78 | # QB: 0
Revenue Correlation: -82.06 | Revenue CAGR: -20.42% | SUE: 0.08 | # QB: 0
Market Cap EUR = 26.87b (26.87b EUR * 1.0 EUR.EUR)
P/E Trailing = 23.6139
P/E Forward = 13.089
P/S = 1.2061
P/B = 1.4529
P/EG = 0.3848
Beta = 1.016
Revenue TTM = 22.23b EUR
EBIT TTM = 2.21b EUR
EBITDA TTM = 3.33b EUR
Long Term Debt = 9.31b EUR (from longTermDebt, last quarter)
Short Term Debt = 2.26b EUR (from shortTermDebt, last quarter)
Debt = 12.85b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 11.63b EUR (from netDebt column, last quarter)
Enterprise Value = 38.33b EUR (26.87b + Debt 12.85b - CCE 1.39b)
Interest Coverage Ratio = 5.83 (Ebit TTM 2.21b / Interest Expense TTM 379.0m)
FCF Yield = 3.23% (FCF TTM 1.24b / Enterprise Value 38.33b)
FCF Margin = 5.57% (FCF TTM 1.24b / Revenue TTM 22.23b)
Net Margin = 5.06% (Net Income TTM 1.12b / Revenue TTM 22.23b)
Gross Margin = 25.40% ((Revenue TTM 22.23b - Cost of Revenue TTM 16.58b) / Revenue TTM)
Gross Margin QoQ = 26.12% (prev 24.97%)
Tobins Q-Ratio = 0.93 (Enterprise Value 38.33b / Total Assets 41.32b)
Interest Expense / Debt = 0.67% (Interest Expense 86.0m / Debt 12.85b)
Taxrate = 29.74% (146.0m / 491.0m)
NOPAT = 1.55b (EBIT 2.21b * (1 - 29.74%))
Current Ratio = 1.31 (Total Current Assets 10.88b / Total Current Liabilities 8.30b)
Debt / Equity = 0.70 (Debt 12.85b / totalStockholderEquity, last quarter 18.28b)
Debt / EBITDA = 3.49 (Net Debt 11.63b / EBITDA 3.33b)
Debt / FCF = 9.40 (Net Debt 11.63b / FCF TTM 1.24b)
Total Stockholder Equity = 19.01b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.72% (Net Income 1.12b / Total Assets 41.32b)
RoE = 5.92% (Net Income TTM 1.12b / Total Stockholder Equity 19.01b)
RoCE = 7.80% (EBIT 2.21b / Capital Employed (Equity 19.01b + L.T.Debt 9.31b))
RoIC = 5.02% (NOPAT 1.55b / Invested Capital 30.88b)
WACC = 6.75% (E(26.87b)/V(39.72b) * Re(9.76%) + D(12.85b)/V(39.72b) * Rd(0.67%) * (1-Tc(0.30)))
Discount Rate = 9.76% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 81.65 | Cagr: 0.51%
[DCF Debug] Terminal Value 70.17% ; FCFE base≈2.05b ; Y1≈1.83b ; Y5≈1.56b
Fair Price DCF = 37.64 (DCF Value 21.20b / Shares Outstanding 563.2m; 5y FCF grow -13.08% → 3.0% )
EPS Correlation: 62.41 | EPS CAGR: 10.57% | SUE: 0.78 | # QB: 0
Revenue Correlation: -82.06 | Revenue CAGR: -20.42% | SUE: 0.08 | # QB: 0